The FDA recently ruled bluebird bio’s blood disorder therapy as effective, and William Blair analyst Raju Prasad is quoted on the implications for the company.
Equity Research
William Blair Analyst Raju Prasad Comments on Bluebird Bio in Reuters
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
Our Latest News
-
Economics Weekly: Valuations and Bubbles
In this Economics Weekly we again discuss the issue of a stock market bubble, with the view that parts of the market are very richly valued on some measures and market return expectations should be tempered, but today’s market would not yet seem to qualify as a bubble.
-
-